Resources Repository
-
ReviewPublication 2023Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic …
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic drugs (NIADs) within glucagon-like peptide-1 (GLP1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or dipeptidyl peptidase-4 (DPP4) inhibitors for treating type 2 diabetes mellitus (T2DM). The study focused on economic results and underlying methodological choices. Methods included searching PubMed, Embase, and Econlit databases from January 1, 2018, to November 15, 2022. Two reviewers screened titles, abstracts, and full texts for relevance…
Cost-Effectiveness Analysis | Health/Medicine | Evidence Synthesis | Mathematical Models | Chronic Disease/Risk | Europe -
ReviewPublication 2023Inclusion of Environmental Spillovers in Applied Economic Evaluations of Healthcare Products
This review examines the inclusion of environmental spillovers in economic evaluations of healthcare products and …
This review examines the inclusion of environmental spillovers in economic evaluations of healthcare products and health technology assessments (HTA). Environmental spillovers, such as CO2 emissions, water and energy consumption, and waste disposal, significantly impact human and planetary health but are often excluded from HTAs. The review's objective is to identify economic evaluations and guidelines incorporating environmental dimensions. Methods included electronic searches of PubMed, Scopus, and EMBASE, as well as official health agencies' guidelines. Documents were…
Cost-Effectiveness Analysis | Health/Medicine | Evidence Synthesis | Technology Assessment | Environmental Health | Climate/Environment | Global -
ReviewPublication 2023Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: ISPOR Special Interest Group Report
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes …
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes potential approaches to mitigate them. A multidisciplinary team of biosimilar experts conducted a systematic review of literature and engaged in review rounds to identify these challenges. The article suggests that health technology assessment agencies should accept the comparability exercise approved by regulatory authorities and conduct price comparisons for biosimilars reimbursed for the same indication as the reference biologic. In cases…
Preferences/Values | Health/Medicine | Evidence Synthesis | Technology Assessment | Policy/Regulation -
ReportPublication 2022Investment Case for New Tuberculosis Vaccines
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will …
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will save lives, fight antimicrobial resistance, advance health equity, improve economic growth, and bring a substantial return on investment. This World Health Organization (WHO) report describes the full value proposition for new TB vaccines. These analyses articulate the broader economic impacts of new TB vaccines to guide global stakeholders when making investment decisions for novel TB vaccines and to plan for…
Cost-Effectiveness Analysis | Health/Medicine | Infectious Diseases | Economics/Finance | Global -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Cost-Effectiveness Analysis | Health/Medicine | Evidence Synthesis | Infectious Diseases | Social Determinants | Culture/Society | Economics/Finance | North America -
ReviewPublication 2022Multicriteria Decision Analysis to Support Decision Making in Healthcare
This study reviews the application of multicriteria decision analysis (MCDA) in healthcare, aiming to clarify …
This study reviews the application of multicriteria decision analysis (MCDA) in healthcare, aiming to clarify its use across various decision-making contexts. The authors updated a 2013 systematic review by searching Embase, MEDLINE, and Google Scholar for English-language MCDA studies published from August 2013 to November 2020. Additionally, grey literature from January 1990 to November 2020 was reviewed via the Trip Medical Database and Google. Information on decision context, criteria, methods, stakeholders, and sensitivity analyses was…
Priority Setting/Ethics | Health/Medicine | Evidence Synthesis | Decision Analysis -
ReportPublication 2022Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
The article introduces the CHEERS 2022 statement, an updated set of guidelines for reporting health …
The article introduces the CHEERS 2022 statement, an updated set of guidelines for reporting health economic evaluations. Health economic evaluations compare alternative actions in terms of costs and consequences. The original CHEERS statement, published in 2013, aimed to make these evaluations clear, interpretable, and useful for decision-making by providing a standardized reporting format. Methods involved reviewing advancements in health economic evaluation methods and the need for inclusive stakeholder engagement, including patients and the public. The…
Cost-Effectiveness Analysis | Health/Medicine -
ReportPublication 2021What the American Public Thinks About Vaccines and How Framing Can Help
This paper explores the question of public understandings, beliefs, and attitudes about vaccination in general, …
This paper explores the question of public understandings, beliefs, and attitudes about vaccination in general, and childhood vaccination more specifically. The authors provide an overview of the existing literature on public thinking about vaccination and on effective communication strategies and interventions that have been either suggested or empirically tested. This description was extracted from the publication abstract.
Preferences/Values | Health/Medicine | Infectious Diseases | Child/Nutrition | Social Determinants | Culture/Society | Science/Technology | North America -
ReportPublication 2018Human Development Indices and Indicators: 2018 Statistical Update
This report from the United Nations Development Programme (UNDP) presents the latest reporting on key …
This report from the United Nations Development Programme (UNDP) presents the latest reporting on key human development indices and statistics. It provides a snapshot of current conditions and long-term trends and culminates with a comprehensive statistical annex of human development composite indices and indicators across several dimensions (e.g., health, education, poverty, and inequality). The publication emphasizes that while people are living longer and are more educated than ever before, this may not automatically translate to…
Health Outcomes | Health/Medicine | Evidence Synthesis | Social Determinants | Health Systems | Climate/Environment | Economics/Finance | Education/Labor | Science/Technology | Global